Inovio partner ApolloBio says VGX-3100 Phase 3 cervical dysplasia trial hits endpoint

• Inovio reported that its China partner ApolloBio delivered positive topline results from a pivotal Phase 3 trial of VGX-3100 in cervical dysplasia, meeting the study’s primary efficacy goal with a favorable safety and tolerability profile.
• The data have not yet been presented; the results are expected to be shown at upcoming international medical conferences and published in peer-reviewed journals.
• ApolloBio plans to use the outcome to support a future regulatory filing for VGX-3100 in China.
• Under the partnership terms, Inovio is eligible for up to $20 million in regulatory-approval milestones, net of required taxes, with tiered royalties on annual net sales if the product reaches the market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605211605PR_NEWS_USPR_____PH65728) on May 21, 2026, and is solely responsible for the information contained therein.